Ethyl 5-(4-methoxyphenyl)-1,3,4-oxadiazole-2-carboxylate → 1-[2-Fluoro-4-({1-[(5-phenyl-1,3,4-oxadiazol-2-yl)carbonyl]azetidin-3-yl}oxy)benzyl]-4-methylpiperazine

Participants

Role	Name	HCID	Charge
Reactant	Ethyl 5-(4-methoxyphenyl)-1,3,4-oxadiazole-2-carboxylate	HCID 13407471	—
Reactant	1-(4-(Azetidin-3-yloxy)-2-fluorobenzyl)-4-methylpiperazine	HCID 66653480	—
Product	1-[2-Fluoro-4-({1-[(5-phenyl-1,3,4-oxadiazol-2-yl)carbonyl]azetidin-3-yl}oxy)benzyl]-4-methylpiperazine	HCID 56597990	32%

Reaction Steps

Using a similar protocol as described in Example 10 employing 29D (0.10 g, 0.36 mmol) and ethyl 5-(4-methoxyphenyl)-1,3,4-oxadiazole-2-carboxylate (0.11 g, 0.43 mmol) as starting materials afforded 52 mg (30%) of 29 as a foam.

Provenance & Evidence

DOI	10.6084/m9.figshare.5104873.v1
Patent number	US08546375B2
Source dataset	uspto-grants-2013_10
ORD ID	ord-217b1a61144a42bb88d174d46f96e085
Source note	uspto-grants-2013_10